Peakdale signs collaborative agreement with computational chemistry company Cresset

Peakdale Molecular Limited, a UK-based provider of drug discovery services to the pharmaceutical and biotech industries and part of the Concept Life Sciences Group, has signed a collaboration agreement with computational chemistry company, Cresset.

By partnering with Cresset, Peakdale has further extended its integrated drug discovery offering.

Cresset’s software uses 3D molecular electrostatics and shape to shed light on the properties and behaviours of chemical structures and, crucially, to understand the key interactions which underpin biological behaviour.

Whilst Cresset software allows unique insights into protein-ligand interactions, it is the expertise of the Cresset scientists in interpreting the data and deriving knowledge for future compound design that is so valuable. These services are based on the research into virtual screening technology undertaken by Cresset founder, Dr Andy Vinter.

Commenting on the partnership, Dr David Bardsley, Commercial Director at Cresset, said: 'Global discovery organisations today work with a number of service providers to enable their research efforts. However, there is an important balance to be found between approaching a single integrated service provider and companies trying to select the best expertise for each aspect of their programmes. We are delighted to be working with Peakdale and look forward to delivering our partnership to clients across the world.'

Dr Paul Doyle, Chief Operating Officer at Peakdale Molecular, continued: 'Cresset’s reputation and experience in science and the breadth of understanding in computational problems makes them the ideal collaborator in the fields we are working. By adding their services and importantly, expertise, to the Peakdale offering we have further broadened a key element in our integrated drug discovery offering with world leading science.'